Spero Therapeutics (NASDAQ:SPRO) Downgraded by Wall Street Zen to Sell

by · The Markets Daily

Wall Street Zen lowered shares of Spero Therapeutics (NASDAQ:SPRO – Free Report) from a hold rating to a sell rating in a research report report published on Saturday morning,Wall Street Zen reports.

Several other research firms have also recently commented on SPRO. Cantor Fitzgerald started coverage on Spero Therapeutics in a report on Wednesday. They issued an “overweight” rating and a $6.00 price target for the company. Compass Point raised Spero Therapeutics to a “neutral” rating in a report on Monday, September 14th. Weiss Ratings lowered Spero Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, October 26th. Zacks Research upgraded Spero Therapeutics to a “hold” rating in a research report on Monday, September 14th. Finally, HC Wainwright increased their price objective on Spero Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Monday, September 14th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $6.00.

Read Our Latest Report on SPRO

Spero Therapeutics Stock Performance

Shares of SPRO opened at $1.06 on Friday. The stock has a market capitalization of $61.73 million, a P/E ratio of 9.64 and a beta of 1.50. The company’s fifty day moving average is $1.17 and its two-hundred day moving average is $1.98. Spero Therapeutics has a 1 year low of $1.04 and a 1 year high of $3.08.

Spero Therapeutics (NASDAQ:SPRO – Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.01. Spero Therapeutics had a net margin of 24.90% and a return on equity of 16.17%. Sell-side analysts predict that Spero Therapeutics will post -0.97 EPS for the current year.

Institutional Investors Weigh In On Spero Therapeutics

A number of large investors have recently bought and sold shares of SPRO. Alphabet Inc. acquired a new stake in shares of Spero Therapeutics during the 2nd quarter worth about $1,967,000. BlackRock Inc. purchased a new stake in shares of Spero Therapeutics during the second quarter worth about $1,314,000. Susquehanna Fundamental Investments LLC acquired a new position in shares of Spero Therapeutics in the second quarter valued at approximately $36,000. Global Retirement Partners LLC acquired a new position in shares of Spero Therapeutics in the second quarter valued at approximately $55,000. Finally, GSA Capital Partners LLP acquired a new position in shares of Spero Therapeutics in the second quarter valued at approximately $632,000. Institutional investors and hedge funds own 25.60% of the company’s stock.

About Spero Therapeutics

(Get Free Report)

Spero Therapeutics, Inc (NASDAQ:SPRO) is a biopharmaceutical company focused on developing treatments for multidrug-resistant bacterial infections and certain rare diseases. The company’s research programs are designed to address infections for which existing antibiotics may be inadequate, including complicated urinary tract infections and infections caused by difficult-to-treat pathogens.

Spero’s lead product candidate has been tebipenem pivoxil hydrobromide, an orally administered carbapenem antibiotic developed for the treatment of complicated urinary tract infections.

Featured Articles